Business Wire

1937 Alfa Romeo 8C 2900B Berlinetta Named the Most Prestigious Car in the World

8.2.2019 12:06:00 EET | Business Wire | Press release

Share

Arguably one of the most desirable cars of all time, the remarkable 1937 Alfa Romeo 8C 2900B Berlinetta today was revealed at The Peninsula Paris hotel as the winner of the fourth annual The Peninsula Classics Best of the Best Award.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190208005130/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The 1937 ALFA ROMEO 8C 2900B BERLINETTA was named winner of The Peninsula Classics Best of the Best Award. (Photo: Jana Call me J)

While eight stunning ‘Best of Show’ winners from top concours around the world competed for the accolade, the Alfa Romeo was the stand-out choice among the judges as the best car in the world. Hailing from Los Angeles, California, the car was entered into the running for the award after being named ‘Best of Show’ at the 2018 Pebble Beach Concours d’Elegance.

“The winning Alfa Romeo is a perfect example of the type of car that inspired us to create this award,” said William E. (Chip) Connor, Chairman and CEO of William E. Connor & Associates Ltd, and co-founder of The Peninsula Classics Best of the Best Award. “To provide an opportunity for car lovers to pause a moment and celebrate flawless design and engineering of this calibre is truly an honour each year.”

The Alfa Romeo is owned by David and Ginny Sydorick of Los Angeles, California. Reflecting on the car’s recent recognition, David said: “As an avid auto-collector, having two cars in the running for this year’s award was truly remarkable. It goes without saying that Ginny and I are ecstatic at the result – a proud moment for us both.”

The winning car was unveiled using a ‘shutter-effect’, whereby individual slats turned in sync to reveal the Alfa Romeo standing proudly within a bespoke-designed, up-lit box. Following the big reveal, guests at the party, including ‘Beauty and the Beast,’The Alienist,’ and Girl on a Train’ star Luke Evans, were further treated to a music set from notable DJ and On-Camera Personality, Hannah Bronfman, who was joined by husband, DJ and Entrepreneur, Brendan Fallis.

An automotive jewel engineered by Ingegner Vittorio Jano, the 8C 2900 was designed to compete in sports car races, specifically the Mille Miglia, which it won outright in 1935, 1936, 1937, 1938 and 1947. In racing trim, they dominated all the major competitions, and in road trim, they were the fastest grand touring cars.

Established in 1925 in Milan, Italian coachbuilder Carrozzeria Touring had first licensed Charles Weymann's system of fabric-covered lightweight frames and then developed its own ‘Superleggera’ construction. Patented in 1936, the Superleggera system consists of a structural framework of small-diameter steel tubes that conform to an automobile body's shape and are covered by thin alloy body panels that strengthen the framework. The winning vehicle, 412020, is the first of only five known Berlinettas built on the Lungo chassis and is the car that Touring refers to as the beginning of Superleggera.

About The Peninsula Classics Best of the Best Award

Through a shared desire to celebrate the best of what defines the automotive world, The Hon. Sir Michael Kadoorie, Chairman of The Hongkong and Shanghai Hotels, Limited, launched The Peninsula Classics Best of the Best Award in 2015 with co-founders William E. (Chip) Connor, Bruce Meyer and Christian Philippsen. Each founder shares a common passion and appreciation of fine motor cars, the preservation of their heritage and immaculate restoration projects. The award, sponsored by The Peninsula Hotels, brings together eight of the concours circuits’ elite ‘Best of Show’ winners from around the globe.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Sanaz Marbley/Devon Zahm
JMPR Public Relations
+1 (818) 992 4353
smarbley@jmpr.com / dzahm@jmpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye